B Strober

Summary

Country: USA

Publications

  1. ncbi Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study
    Bruce E Strober
    Department of Dermatology, New York University Medical Center, 550 First Ave, TCH 158, New York, NY 10016, USA
    Arch Dermatol 145:1262-6. 2009
  2. ncbi Alefacept for the treatment of psoriasis and other dermatologic diseases
    Bruce E Strober
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA
    Dermatol Ther 20:270-6. 2007
  3. ncbi Conventional systemic agents for psoriasis. A systematic review
    Bruce E Strober
    New York University School of Medicine, New York, New York 10016, USA
    J Rheumatol 33:1442-6. 2006
  4. ncbi Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis
    B Strober
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA
    Br J Dermatol 159:322-30. 2008
  5. ncbi An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
    A B Gottlieb
    Department of Dermatology, Tufts University, Boston, MA 02111 1533, USA
    Curr Med Res Opin 24:1529-38. 2008
  6. ncbi Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE
    Ellen H Frankel
    Clinical Partners LLC, Cranston, Rhode Island 02910, USA
    Cutis 79:322-6. 2007
  7. ncbi Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    Alan Menter
    Division of Dermatology, Baylor Research Institute, University of Texas Southwestern Medical School, 3900 Junius St, 125, Dallas, TX 75246 1613, USA
    J Am Acad Dermatol 58:106-15. 2008
  8. ncbi Tinea versicolor associated with etanercept therapy
    Marla S Levy
    J Am Acad Dermatol 58:S99-100. 2008
  9. ncbi Off-label dermatologic uses of anti-TNF-a therapies
    Andrew F Alexis
    Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, NY, USA
    J Cutan Med Surg 9:296-302. 2005
  10. ncbi Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study
    Alice B Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Boston, MA 02111 1533, USA
    J Dermatolog Treat 17:343-52. 2006

Collaborators

Detail Information

Publications29

  1. ncbi Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study
    Bruce E Strober
    Department of Dermatology, New York University Medical Center, 550 First Ave, TCH 158, New York, NY 10016, USA
    Arch Dermatol 145:1262-6. 2009
    ..To assess the efficacy of alefacept for the treatment of severe alopecia areata (AA)...
  2. ncbi Alefacept for the treatment of psoriasis and other dermatologic diseases
    Bruce E Strober
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA
    Dermatol Ther 20:270-6. 2007
    ..Some patients who achieve PASI 75 also experience long-term remissions from psoriasis. The drug is well-tolerated and adverse events are rare. Off-label use of the drug is growing and may be formally explored in the future...
  3. ncbi Conventional systemic agents for psoriasis. A systematic review
    Bruce E Strober
    New York University School of Medicine, New York, New York 10016, USA
    J Rheumatol 33:1442-6. 2006
    ..This is a systematic, evidence-based review of the literature evaluating both the efficacy and safety of the medications cyclosporine, methotrexate, acitretin, hydroxyurea, and 6-thioguanine. Treatment recommendations are made...
  4. ncbi Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis
    B Strober
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA
    Br J Dermatol 159:322-30. 2008
    ..C-reactive protein (CRP), an inflammation biomarker, indicates cardiovascular risk and is elevated in psoriasis. The effect of etanercept on CRP in psoriasis has not been previously examined...
  5. ncbi An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
    A B Gottlieb
    Department of Dermatology, Tufts University, Boston, MA 02111 1533, USA
    Curr Med Res Opin 24:1529-38. 2008
    ..To evaluate the clinical and biological activity of apremilast in patients with severe plaque-type psoriasis...
  6. ncbi Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE
    Ellen H Frankel
    Clinical Partners LLC, Cranston, Rhode Island 02910, USA
    Cutis 79:322-6. 2007
    ..We present data on patient-reported outcomes (PROs) from EDUCATE, which demonstrate that subjects with PsA achieved clinically meaningful improvements in both skin- and joint-related PROs after 24 weeks of treatment...
  7. ncbi Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    Alan Menter
    Division of Dermatology, Baylor Research Institute, University of Texas Southwestern Medical School, 3900 Junius St, 125, Dallas, TX 75246 1613, USA
    J Am Acad Dermatol 58:106-15. 2008
    ..Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis...
  8. ncbi Tinea versicolor associated with etanercept therapy
    Marla S Levy
    J Am Acad Dermatol 58:S99-100. 2008
  9. ncbi Off-label dermatologic uses of anti-TNF-a therapies
    Andrew F Alexis
    Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, NY, USA
    J Cutan Med Surg 9:296-302. 2005
    ..CONCLUSIONS: A growing number of published reports suggest that anti-TNF-a therapies may be effective in the treatment of numerous inflammatory skin diseases outside their currently approved indications...
  10. ncbi Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study
    Alice B Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Boston, MA 02111 1533, USA
    J Dermatolog Treat 17:343-52. 2006
    ..To assess the efficacy and tolerability of etanercept to treat psoriatic arthritis...
  11. ncbi Folate supplementation during methotrexate therapy for patients with psoriasis
    Bruce E Strober
    Department of Dermatology, New York University School of Medicine, New York, New York, USA
    J Am Acad Dermatol 53:652-9. 2005
    ..After examining the available data from the literature and drawing from clinical experience, we advise folate supplementation for every patient who receives methotrexate...
  12. ncbi Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab
    Bruce E Strober
    Arch Dermatol 140:366. 2004
  13. ncbi Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study
    Bruce E Strober
    The Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA
    J Am Acad Dermatol 52:1082-4. 2005
    ..Based on these results, etanercept appears to be ineffective in treating subjects with treatment-refractory, moderate to severe alopecia areata, alopecia totalis, or alopecia universalis...
  14. ncbi The treatment of psoriasis with etanercept
    Bruce E Strober
    Dermatopharmacology Unit, Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
    Semin Cutan Med Surg 24:28-36. 2005
    ..With appropriate patient selection and follow-up, etanercept therapy has a very good benefit-to-risk ratio and represents a convenient option for patients with moderate-to-severe psoriasis...
  15. ncbi Etanercept for the treatment of psoriasis: combination therapy with other modalities
    Bruce E Strober
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, USA
    J Drugs Dermatol 3:270-2. 2004
    ..Below are cases that demonstrate how etanercept can be combined with other medications in order to both maximize clinical efficacy and minimize potential risk...
  16. ncbi Efalizumab-associated Guillain-Barre syndrome
    Frank Victor
    Arch Dermatol 144:1396-7. 2008
  17. ncbi National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
    Alexa B Kimball
    Department of Dermatology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Am Acad Dermatol 58:1031-42. 2008
    ....
  18. ncbi Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab
    Shana Marmon
    Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA
    J Invest Dermatol 128:2567-9. 2008
    ..this issue) investigated these issues by testing the immune response to both a model antigen and a therapeutic vaccination in psoriasis patients during and after treatment with an LFA-1 inhibitor, efalizumab...
  19. ncbi Substantial alterations of the cutaneous bacterial biota in psoriatic lesions
    Zhan Gao
    Department of Medicine, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 3:e2719. 2008
    ..001), whereas normal skin from the psoriatic patients showed intermediate levels (12.3+/-21.6%). We conclude that psoriasis is associated with substantial alteration in the composition and representation of the cutaneous bacterial biota...
  20. ncbi Reconsidering liver biopsies during methotrexate therapy
    Jeffery S Henning
    J Am Acad Dermatol 56:893-4. 2007
  21. ncbi The potential of interleukin 12 inhibition in the treatment of psoriasis
    David Rosmarin
    Ronald O. Perelman Department of Dermatology, NYU School of Medicine, New York, NY, USA
    J Drugs Dermatol 4:318-25. 2005
    ..Some effective conventional psoriasis treatments alter IL-12 levels. Importantly, specific antibodies directed against IL-12 may prove useful against psoriasis but may also act by targeting IL-23 in addition to IL-12...
  22. ncbi Alefacept in the treatment of psoriatic nail disease: a small case series
    Christopher T Cassetty
    J Am Acad Dermatol 52:1101-2. 2005
  23. ncbi Successful treatment of plaque psoriasis with self-administered subcutaneous alefacept
    Bruce E Strober
    Arch Dermatol 141:1602. 2005
  24. ncbi Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study
    James Leyden
    Skin Study Center, Broomall, PA, USA
    Arch Dermatol 142:605-12. 2006
    ..To evaluate the efficacy of 3 maintenance regimens (topical tazarotene, oral minocycline hydrochloride, or both) in sustaining improvement in acne...
  25. ncbi A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis
    Donald Belsito
    University of Missouri, Kansas City, USA
    J Am Acad Dermatol 55:40-6. 2006
    ..CONCLUSIONS: Tacrolimus ointment 0.1% is well tolerated and significantly more effective than vehicle in treating chronically exposed, nickel-induced ACD...
  26. ncbi Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions
    Luciana C Paulino
    Department of Medicine, New York University School of Medicine, 550 First Ave, OBV-A 606, New York, NY 10016, USA
    J Clin Microbiol 44:2933-41. 2006
    ..These data indicate the predominance of Malassezia organisms in healthy human skin, host-specific variation, stability over time, and as yet, no consistent patterns differentiating psoriatic skin from healthy skin...
  27. ncbi On multiple courses of alefacept
    Craig L Leonardi
    J Am Acad Dermatol 55:916-7. 2006
  28. ncbi National Psoriasis Foundation clinical consensus on disease severity
    David M Pariser
    Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA
    Arch Dermatol 143:239-42. 2007
    ....
  29. ncbi The Köbner phenomenon and psoriatic arthritis
    Ritu Saini
    New York University School of Medicine, Ronald O. Perelman Department of Dermatology, New York, New York, USA
    Cutis 72:405-6. 2003
    ..Dermatologists should screen patients with psoriasis for accompanying PsA and consider recently traumatized joints that remain arthritic to be a component of this disease...